CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
LY3202626 (R-Fasting) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03023826
NCT03023826Phase 1Completed
CompareCT.gov

Relative Bioavailability and Food Effect Study in Healthy Subjects Administered Two Different Formulations of LY3202626

Eli Lilly and Company·interventional·Posted Jan 18, 2017·Updated Apr 19, 2021

In Brief

A Phase 1 clinical trial evaluating LY3202626 (R-Fasting), LY3202626 (T1-Fasting), and 1 other intervention for Healthy. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purposes of this study are to determine: * If there are any differences in the way LY3202626 is handled by the body when taken in two different forms * Whether a high fat meal affects the way the body handles LY3202626 * How well tolerated LY3202626 is There are three (3) study periods for all participants. Participants will be admitted to the clinical research unit (CRU) each period and will be discharged from the CRU following the completion of 2 overnight stays and up to 36 hours after dosing with LY3202626. The study will last about 50 days, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 18, 2017
Enrollment StartJan 15, 2017
Primary CompletionApr 4, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.5 years ago

Interventions

LY3202626 (R-Fasting)drug

Administered orally

LY3202626 (T1-Fasting)drug

Administered orally

LY3202626 (T1-Fed)drug

Administered orally